[go: up one dir, main page]

DE3852221D1 - Tierische Zelle mit darin eingeführtem antigenem Protein. - Google Patents

Tierische Zelle mit darin eingeführtem antigenem Protein.

Info

Publication number
DE3852221D1
DE3852221D1 DE3852221T DE3852221T DE3852221D1 DE 3852221 D1 DE3852221 D1 DE 3852221D1 DE 3852221 T DE3852221 T DE 3852221T DE 3852221 T DE3852221 T DE 3852221T DE 3852221 D1 DE3852221 D1 DE 3852221D1
Authority
DE
Germany
Prior art keywords
cells
modified
aids
virus
erythrocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3852221T
Other languages
English (en)
Other versions
DE3852221T2 (de
Inventor
Yves C Nicolau
Garret M Ihler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hapgood CV
Original Assignee
Hapgood CV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26748809&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3852221(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hapgood CV filed Critical Hapgood CV
Application granted granted Critical
Publication of DE3852221D1 publication Critical patent/DE3852221D1/de
Publication of DE3852221T2 publication Critical patent/DE3852221T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/5432—Liposomes or microcapsules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
    • G01N33/555—Red blood cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
DE3852221T 1987-06-30 1988-06-14 Tierische Zelle mit darin eingeführtem antigenem Protein. Expired - Fee Related DE3852221T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6828887A 1987-06-30 1987-06-30
US19744588A 1988-05-27 1988-05-27

Publications (2)

Publication Number Publication Date
DE3852221D1 true DE3852221D1 (de) 1995-01-12
DE3852221T2 DE3852221T2 (de) 1995-04-06

Family

ID=26748809

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3852221T Expired - Fee Related DE3852221T2 (de) 1987-06-30 1988-06-14 Tierische Zelle mit darin eingeführtem antigenem Protein.

Country Status (9)

Country Link
US (1) US5677176A (de)
EP (1) EP0298280B1 (de)
JP (2) JP2728166B2 (de)
AT (1) ATE114476T1 (de)
AU (2) AU1821988A (de)
CA (1) CA1327332C (de)
DE (1) DE3852221T2 (de)
ES (1) ES2067457T3 (de)
IL (1) IL86650A0 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310654A (en) * 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
US5236835A (en) * 1988-10-05 1993-08-17 Hapgood, C.V. Electro insertion of proteins into red cell membranes
CA1327174C (en) * 1988-10-05 1994-02-22 Youssef Mouneimne Electro-insertion of proteins into animal cell membranes
KR910700291A (ko) * 1988-12-22 1991-03-14 리챠드 지. 워터맨 헤테로사이클릭 중합체의 개선된 합성방법
JP3414395B2 (ja) * 1990-10-19 2003-06-09 ユニバーシティー オブ フロリダ 人工的に製造したウィルスのエンベロープ
US5252348A (en) * 1990-10-19 1993-10-12 Univ. Of Florida Research Foundation, Inc. Artificial viral envelopes
US5753258A (en) * 1990-10-19 1998-05-19 University Of Florida Artificial viral envelopes
PL296382A1 (en) * 1991-02-02 1993-11-02 Nika Health Products Ltd Li Li Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system
ES2109260T3 (es) * 1991-06-14 1998-01-16 Europ Communities Eritrocitos transformados, procedimiento para prepararlos y su utilizacion en composiciones farmaceuticas.
GB9219562D0 (en) 1992-03-11 1992-10-28 Prendergast Kennet F Anti-viral peptides
DE69329145D1 (de) * 1992-03-11 2000-09-07 Kenneth Francis Prendergast Anti-virale Fusionspeptide
AU5014393A (en) * 1992-08-13 1994-03-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The The use of cd4 plasma membrane vesicles (pmv) as a therapeutic agent for aids
CA2144767A1 (en) * 1992-09-22 1994-03-31 Guerard W. Byrne Delivery of proteins by intermembrane transfer for preaccommodation of xenogeneic organ transplants and other purposes
US5840328A (en) * 1994-01-11 1998-11-24 The Liposome Company, Inc. Treatment using arachidonic acid metabolite and particulate formulations
HUT76331A (en) * 1994-07-15 1997-08-28 Lepetit Spa Dinucleoside-5',5'-pyrophosphates
US5591448A (en) * 1994-11-21 1997-01-07 Tepic; Slobodan Anti-viral therapeutic composition
US5834015A (en) * 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
GB9721901D0 (en) 1997-10-16 1997-12-17 Univ Manchester Particles
AU1734600A (en) * 1998-11-17 2000-06-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Identification of glycosphingolipids that promote hiv-1 entry into cells
ATE272391T1 (de) 1998-12-23 2004-08-15 Idea Ag Verbesserte formulierung zur topischen, nichtinvasiven anwendung in vivo
SI1031346T1 (en) 1999-01-27 2002-08-31 Idea Ag Noninvasive vaccination through the skin
ES2173679T3 (es) 1999-01-27 2002-10-16 Idea Ag Inmunizacion/transporte transnasal con vehiculos altamente adaptables.
EP1921451A3 (de) * 2001-05-22 2008-05-28 Cygene, Inc. Komplement-vermittelte Assays für In-vivo- und In-vitro-Verfahren
WO2003034074A1 (en) * 2001-10-16 2003-04-24 Kiwi Ingenuity Limited Sensitivity controls for blood serology prepared from modified cells
US20050032113A1 (en) * 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
CN102046151A (zh) * 2008-03-26 2011-05-04 牛津大学 靶向内质网的脂质体
US20110070153A1 (en) * 2008-08-13 2011-03-24 Searete, Llc, A Limited Liability Corporation Of The State Of Delaware Artificial cells
US8211656B2 (en) 2008-08-13 2012-07-03 The Invention Science Fund I, Llc Biological targeting compositions and methods of using the same
US20100042072A1 (en) * 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
US20100040546A1 (en) * 2008-08-13 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Biological targeting compositions and methods of using the same
WO2011044369A1 (en) 2009-10-08 2011-04-14 Otsuka Pharmaceutical Co., Ltd. An immunoactivation blood perfusion filter for the treatment of malignant tumors
AU2014348683B2 (en) 2013-11-18 2020-11-05 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
KR20170005801A (ko) 2014-04-01 2017-01-16 루비우스 테라퓨틱스, 아이엔씨. 면역조절을 위한 방법 및 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA806506B (en) * 1979-11-01 1981-09-30 Bio Response Inc A method for production of monoclonal antibodies
DE3218121A1 (de) * 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
FR2564319A1 (fr) * 1984-05-21 1985-11-22 Inst Nat Sante Rech Med Nouvelles compositions de liposomes dotees d'une action specifique vis-a-vis de la proliferation de cellules donnees
US5236835A (en) * 1988-10-05 1993-08-17 Hapgood, C.V. Electro insertion of proteins into red cell membranes

Also Published As

Publication number Publication date
ES2067457T3 (es) 1995-04-01
EP0298280B1 (de) 1994-11-30
JPH01124382A (ja) 1989-05-17
AU1821988A (en) 1989-04-27
JPH1072368A (ja) 1998-03-17
AU1942692A (en) 1992-09-24
EP0298280A2 (de) 1989-01-11
IL86650A0 (en) 1988-11-30
AU662154B2 (en) 1995-08-24
US5677176A (en) 1997-10-14
ATE114476T1 (de) 1994-12-15
JP2825804B2 (ja) 1998-11-18
JP2728166B2 (ja) 1998-03-18
DE3852221T2 (de) 1995-04-06
CA1327332C (en) 1994-03-01
EP0298280A3 (en) 1990-05-02

Similar Documents

Publication Publication Date Title
DE3852221D1 (de) Tierische Zelle mit darin eingeführtem antigenem Protein.
ES8503951A1 (es) Un procedimiento para preparar un complejo inmunogenico que contiene proteinas o peptidos antigenicos
ES2091861T3 (es) Proteinas antigenicas y vacunas que las contienen para la prevencion de la coccidiosis.
IL89701A0 (en) Recombinant retroviruses,method for the production thereof and pharmaceutical composition containing the same
ES2099066T3 (es) Antigenos a partir de adn sintetico derivado del virus de la inmunodeficiencia humana (hiv-1).
DE69033700D1 (de) Il-11 aus säugetier
EP0158277A3 (de) Implantierbare Zubereitungen von regulatorischen Peptiden mit gesteuerter Freisetzung und Verfahren zur ihrer Herstellung
SE8703225L (sv) Monoklonala antikroppar och peptider anvendbara vid behandling och diagnostisering av hiv-infektioner
Wivel et al. Structural organization of murine intracisternal A particles
GR3007031T3 (de)
Sonozaki et al. The macrophage disappearance reaction: II. Mediation by lymphocytes which lack complement receptors
EP0236977A3 (de) Impfstoffe gegen Rindervirus-Diarrhoe und Schweine-Cholera
Hale et al. Antigen-liposome modification of target cells as a method to alter their susceptibility to lysis by cytotoxic T lymphocytes.
RU94040393A (ru) Синтетические пептиды для вакцины против краснухи
DK373489D0 (da) Rekombinante hybrid-partikler med morphologiske egenskaber svarende til antigenet hbsag og omfattende en immunogen sekvens, der inducerer neutraliserende antistoffer rettet mod hiv-retrovirus eller som kan genkendes af saadanne antistoffer, samt vaccine paa basis af saadanne partikler
IT8621230A1 (it) Policarbonati ramificati contenenti acidi alifatici policarbossilici o loro derivati e procedimento per la loro preparazione
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
Iwata et al. Identification of human H‐Y antigen and its testis‐organizing function
Van Den Heuvel et al. Isolation of a bovine plasma fibronectin-containing complex which inhibits the expression of bovine leukemia virus p24
EP0283443A3 (en) Process for extracting membrane antigens having immunogenic properties from human neoplastic cells and products thereby obtained
DK145988D0 (da) Genteknologisk fremstillet 140 kd-antigen af plasmodium falciparum og dettes anvendelse
ES2011679A6 (es) Procedimiento para la preparacion de polipeptidos sinteticos secuenc iales inmunologicamente activos.
Pearse Structure of coated pits and vesicles
JH Humphrey The Value of Immunological Concepts in Medicine: The Croonian Lecture 1981
Callahan et al. Rat Cell Surface Antigens: II. Isolation of a Minor Histocompatibility Antigen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee
8370 Indication related to discontinuation of the patent is to be deleted
8339 Ceased/non-payment of the annual fee